Cefotaxime pharmacokinetics in Arabian camel (Camelus dromedarius) calves after single intravenous injection

Altayban, Abdullah; Kandeel, Mahmoud; Tahoun, Amin; Al‐Nazawi, Mohammed

doi:10.1007/s11250-019-02080-0

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, CFT concentration in shrimp plasma showed a longer elimination half-life (T 1/2el = 8.78 h) compared with other animals, i.e., in buffalo calves (T 1/2el = 0.94 h) [31] or goats (T 1/2el = 1.03 h) [53]. However, the elimination of CFT in this study was faster than that in Arabian camels (15.46 h) [28]. In addition, the C max value of CFT in shrimp plasma (0.18 µg/mL) was much lower than that reported in some fish species when using antibiotics of the same group, i.e., cephalosporins.…”

Section: Cefotaxime Pharmacokinetics In White Leg Shrimpcontrasting

confidence: 52%

“…In Egypt, CFT is used in bacterial pathogen management in tilapia [27]. In aquatic animals, studies related to side effects or pharmacokinetics of CFT are not common, and CFT was just investigated in tilapia (Oreochromis niloticus) in bacterial infectious treatment [27], but CFT PK has been studied in several terrestrial animals like goats (Capra hircus), buffalo calves (Bubalus bubalis), rats and camels (Camelus dromedarius) [28][29][30][31]. CFT is used to control susceptible bacterial infections in aquatic and terrestrial animals, such as tilapia, horses, birds, dogs, cats and reptiles at the dose of 10-80 mg/kg body weight via intraperitoneal, intramuscular, intravenous or subcutaneous injection [27].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetics and Withdrawal Times of Cefotaxime in White Leg Shrimp (Litopenaeus vannamei) after Oral Administration

Huynh,

Scippo,

Devreese

et al. 2024

Fishes

View full text Add to dashboard Cite

A high-performance liquid chromatography method coupled to tandem mass spectrometry was validated in order to study the pharmacokinetics of cefotaxime in shrimp hepatopancreases and plasma, as well as its withdrawal time related to a maximum residue limit (MRL) in shrimp muscle. Pharmacokinetics parameters were investigated through oral medication at a single dose of 25 mg/kg shrimp body weight and subsequent hepatopancreas and plasma cefotaxime concentration measurements at 0.5, 1, 2, 4, 8, 12 and 24 h after shrimp were fed with medication. The maximum concentration of cefotaxime was observed after one hour in the hepatopancreas (Cmax, 19.45 ± 2.10 mg/kg) and 4 h in plasma (0.184 ± 0.061 mg/L). Based on a minimum inhibitory concentration (MIC) of cefotaxime of 4.13 mg/L against Vibrio parahaemolyticus (known to cause acute hepatopancreatic necrosis disease (AHPND) in white leg shrimp), it was observed that the time during which the hepatopancreas cefotaxime concentration was above the MIC was 23 h. An every 24 h cefotaxime treatment could thus be effective in fighting against this bacterium in shrimp. The withdrawal time of cefotaxime was determined after shrimp were fed with medicated feed once a day and twice a day for three consecutive days. Shrimp muscle was collected on day 1 and day 3 during medication and 1, 3, 7, 14 and 21 days after medication was stopped. Considering an MRL of 50 μg/kg, the withdrawal times were 8.5 degree-days (corresponding to 6.9 h at 29.5 °C) after shrimp were fed with medicated feed once a day for 3 days and 95.5 degree-days (77.7 h at 29.5 °C) after shrimp were fed with medicated feed twice a day for 3 days. Moreover, histological analysis revealed that feeding shrimp with cefotaxime at the given dose in once- or twice-a-day treatments did not negatively impact the shrimp hepatopancreas.

show abstract

Section: Cefotaxime Pharmacokinetics In White Leg Shrimpcontrasting

confidence: 52%